ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 89.9 | 88.6 | 74.0 |
| Other income | 1.6 | 0.4 | 1.1 |
| Total income | 91.6 | 89.1 | 75.1 |
| Profit before exceptional items & tax | 1.9 | 1.1 | 0.7 |
| Profit before tax | 1.9 | 1.1 | 0.7 |
| Net profit | 1.4 | 1.1 | 0.7 |
| Operating margin | 2.1% | 1.2% | 0.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +100.00% |
|---|---|
| Net profit, quarter on quarter | +27.30% |
| Revenue, year on year | +21.50% |
| Operating profit, year on year | +175.00% |
| Operating profit, quarter on quarter | -57.10% |
BSE results filing, NSE: BALPHARMA. Figures extracted from the filing.
Bal Pharma Ltd: key numbers
- Share price
- ₹83.67
- Market cap
- ₹133.2 Cr
- Revenue (annual)
- ₹311.7 Cr
- Net profit (annual)
- ₹6.28 Cr
- P/E (TTM)
- 18.5×Sector 43.4×
- Promoter holding
- 50.86%+0.00% QoQ
- FII holding
- 0.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bal Pharma Ltd
All →Bal Pharma Other Announcement
Bal Pharma filed a Reg 32 statement confirming no deviation in its ₹2.10 Cr preferential warrant proceeds, with nothing utilised by September 30, 2026. The amount remains fully unutilised.
- Value
- ₹2.10 Cr
Bal Pharma Board Meeting Date
Bal Pharma Limited informs exchanges of a board meeting on November 11, 2026, to consider unaudited standalone and consolidated results for Q2 FY2026-27. This is a prior intimation with no results figures attached yet.
Bal Pharma Other Announcement
Bal Pharma Ltd has filed its quarterly shareholding pattern as mandated under Regulation 31(1)(b) of the SEBI Listing Regulations.
Bal Pharma Dividend
Bal Pharma disbursed its FY25-26 final dividend of ₹1.20 per share on October 9, 2026. Dividends for shareholders with incomplete KYC or bank details have been withheld.
Bal Pharma Management Change
Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.
Bal Pharma Annual General Meeting
Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.